Pharma News, 2022

ImmunityBio, Inc., a clinical-stage immunotherapy company, announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer (NK) cells in people living ...

Oxford Biomedica, a UK-based gene and cell therapy company, has agreed to form a joint venture (JV) to undertake an adeno-associated virus (AAV) manufacturing and innovation business in the US with...

Eli Lilly and Company (Lilly) said that it will invest more than $1 billion to build a new manufacturing plant in Concord, North Carolina.

After disappointing phase 2 results, Pfizer and Ionis Pharmaceuticals have scrapped their development program for vupanorsen for heart disease and severe hyperglyceridemia indications. ...

BeiGene, a global, science-driven biotechnology company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental...

The European Commission has granted Pfizer’s Lorviqua (lorlatinib) — branded in the U.S. as Lorbrena — marketing authorization as a first-line treatment for adults with anaplastic lymphoma ki...

Glenmark Pharmaceuticals Ltd on Thursday said its US subsidiary has received final approval from the country’s health regulator (FDA) for its generic Bisoprolol Fumarate and Hydrochlorothiazide t...

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and...

Samsung Biologics announced Thursday that it has agreed to buyout Biogen's stake in their nearly decade-long biosimilars joint venture Samsung Bioepis for $2.3 billion.  ...

IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antig...

Merck & Co said the U.S. Food and Drug Administration declined to approve its experimental drug for the treatment of chronic cough and sought additional information on the treatment's effective...

COVID-19 vaccine luminaries Pfizer and BioNTech study will examine data from the current booster and consider need for specific Omicron jab.